Stockreport

VolitionRx up 14% on encouraging data on Nu.Q in prostate cancer [Seeking Alpha]

VolitionRX Limited  (VNRX) 
NASDAQ:AMEX Investor Relations: ir.volitionrx.com
PDF VolitionRx up 14% on encouraging data on Nu.Q in prostate cancer [Read more]